Clinical trial · Observational
Prospective Observational Trial to Evaluate Quality of Life After Stereotactic Ablative Radiation Therapy in Patients With Hepatocellular Carcinoma
NCT03253536CI-TRIAL-00029148LIVERCARErecruitingClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Prospective single arm, single center observational study to evaluate Quality of Life (Qol) after stereotactic body radiotherapy for patients with hepatocellular cancer. Patients will receive work-up, treatment and follow-up exclusively as routinely done except additional quality of life measurements. Qol will be measured by standardized and validated EORTC questionaires at different time points during routine follow-up.
Conditions
Conditions (4)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Hepatocellular Cancer | Hepatocellular Carcinoma | CURATED_BROADER | 0.80 |
| Observational | — | UNRESOLVED | — |
| Quality of Life | — | UNRESOLVED | — |
| Stereotactic Body Radiation Therapy | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| observational | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- label
- entire cohort
- description
- none (observational study)
- interventionNames
- Other: observational
Primary outcomes (1)
- measure
- Quality of life
- timeFrame
- 60 months
- description
- Quality of life
Secondary outcomes (11)
- measure
- acute toxicity
- timeFrame
- 3 months
- description
- physician-related acute toxicity
- measure
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * histologically or radiologically proven hepatocellular carcinoma * 1-3 lesions suitable for stereotactic radiation therapy * indication for SBRT according to multidisciplinary board evaluation * age \>= 18 years * written informed consent for study participation * mental and verbal ability to complete standardized questionaires according to assessment by investigator (physician) Exclusion Criteria: * age \< 18 years * prior HCC specific systemic therapy * concurrent oncological systemic treatment * distant metastases * inadequate ability tobe compliant with the protocol or to complete standardizes questionaires * inability to receive contrast-enhanced planning CT * missing ability to give informed consent * legal custody
References
Publications (0)
Data not yet available
No reference posted for this study.